Putting Americans First

It’s Time to Simplify the System

America leads the world in biotechnology innovation. Yet the U.S. remains the only country where half of every dollar spent on medicine goes to middlemen and supply chain markups - rather than to patients or innovation.

International price setting would devastate these American innovators, undermine investment in early-stage companies, weaken U.S. competitiveness, and slow the development of lifesaving treatments—all while ignoring the true drivers of drug costs.

Let's solve the real problem. Say no to international price setting - and yes to simplifying the system.

Implement Strong PBM Reform: PBM "middlemen" abuse across the health care system has driven patients toward higher-cost drugs, inflating the price of medicines that should be affordable, and siphoning off billions through hidden fees. Strong PBM reform can begin to break the link between PBM fees and drug prices.
Fix the 340B Drug Discount Program: Over the years, the 340B Drug Discount Program has expanded well past the original intent of Congress. The explosive growth of the program is creating ripple effects that are raising the cost of health care for others and not serving the needs of the most vulnerable patients.
Increase Data Transparency: Due to the design of health insurer plans, employers often don't have full access to data about health plan drug pricing. This drives up employer premiums while insurance companies receive significant rebates. Employers should have full access to data about health plan drug pricing and better analytic tools.

Patients Pay. Middlemen Take. Innovation Loses.

Dig deeper into the data to see how billions of dollars are flowing to many entities that add no real value to patient care.

View More Data

How To Empower Patients Through Smarter, Simpler Reforms

International price setting threatens patient access and undermines American leadership in biotechnology.

View One Pager

Putting Americans First: Importing European prices means importing European systems and values

European countries don’t just pull prices for medicines out of thin air. The prices that those governments set are based on specific sets of assumptions about their citizens and their economies.

Putting Americans First: No medicine is more expensive than the one patients can’t access

The most notable differences between the pharmaceutical market in the U.S. and those in other countries are not in the prices. They’re in the ability of the citizens to access breakthrough innovation.

Putting Americans First: International prices in context

It is often taken as a given that drug prices in the U.S. are higher than those in other nations. And while there is a difference in price, that difference is often exaggerated and taken out of context.